KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short-term Investments: 2009-2017

Historic Short-term Investments for Teva Pharmaceutical Industries (TEVA) over the last 8 years, with Dec 2017 value amounting to $25.0 million.

  • Teva Pharmaceutical Industries' Short-term Investments fell 71.59% to $25.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was $25.0 million, marking a year-over-year decrease of 71.59%. This contributed to the annual value of $25.0 million for FY2017, which is 71.59% down from last year.
  • As of FY2017, Teva Pharmaceutical Industries' Short-term Investments stood at $25.0 million, which was down 71.59% from $88.0 million recorded in FY2016.
  • Teva Pharmaceutical Industries' Short-term Investments' 5-year high stood at $105.0 million during FY2015, with a 5-year trough of -$366.0 million in FY2013.
  • In the last 3 years, Teva Pharmaceutical Industries' Short-term Investments had a median value of $88.0 million in 2016 and averaged $72.7 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first crashed by 9,250.00% in 2013, then skyrocketed by 122.40% in 2014.
  • Teva Pharmaceutical Industries' Short-term Investments (Yearly) stood at -$366.0 million in 2013, then surged by 122.40% to $82.0 million in 2014, then increased by 28.05% to $105.0 million in 2015, then fell by 16.19% to $88.0 million in 2016, then crashed by 71.59% to $25.0 million in 2017.